IBRI, Lilly, Dow Agro Detail Data Partnership
The Indiana Biosciences Research Institute is located in the 16 Tech Biotechnology Research & Training Center.
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThe Indiana Biosciences Research Institute is partnering with two of the state’s biggest names in the industry on a shared data platform. The collaboration with Eli Lilly and Co. (NYSE: LLY) and Dow AgroSciences LLC will focus on potential human health and environmental side effects of using different molecules.
The IBRI says increasing the accuracy of early assessments of molecular safety can help save time and money. It says a "fail fast" model helps researchers focus on molecules that are "more likely to meet regulatory requirements and societal expectations" and they can make decisions on the safety of compounds earlier in the process.
IBRI Chief Executive Officer David Broecker says "this is great example of a collaboration that combines the expertise of two leading life science companies focused on different areas of innovation to create unique capabilities that will improve the speed and quality of future development. While Dow AgroSciences and Lilly will use this technology for their own purposes, we will be creating a capability that will be made publicly available to expand learning and accelerate discovery not only here at the IBRI, but with other academic research institutions."
The IBRI, Lilly and Dow AgroSciences will develop a platform analyzing past toxicological and safety assessment data for use in future molecular research and aim to use best practices to increase the efficiency of data analysis.
You can connect to more about the partnership by clicking here.